Markedly elevated serum total N-terminal propeptide of type I collagen is a novel marker for the diagnosis and follow-up of patients with POEMS syndrome Chen Wang 
Main text
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) is a rare plasma-cell dyscrasia [1, 2] . Its diagnosis relies on both clinical and laboratory features, and osteosclerosis is a major diagnostic criterion [3] .
Although conventional imaging methods, including X-ray and computed tomography, can be informative, these techniques are neither sensitive nor specific to detect the sclerotic changes [4] [5] [6] . N-Terminal propeptide of type I collagen (P1NP) is the cleavage product of type I collagen, which constitutes 90% of the bone protein. Because its intraindividual variability is low, sample stability is robust, and high-throughput measurements are possible, serum P1NP is a newly emergent marker of bone formation, and has shown its clinical values in the detection of osteosclerotic metastases in cancer patients [7] . Therefore, serum P1NP might also be useful to reflect the osteosclerosis in POEMS syndrome. Herein, we evaluated the diagnostic significance of serum P1NP in 45 newly diagnosed patients with POEMS syndrome (Supplementary table) . Healthy volunteers (n = 28) and patients with disease manifestations similar to those of POEMS syndrome, including chronic inflammatory demyelinating polyneuropathy (CIDP) (n = 18), Castleman's disease (CD) (n = 11), multiple myeloma (MM) (n = 15) and primary light-chain amyloidosis (AL) (n = 10), were used as normal and disease controls, respectively.
The serum levels of total P1NP in patients with POEMS syndrome were markedly elevated (median 137 ng/mL; range, 18-792 ng/mL), compared with those of the normal subjects (median 35 ng/mL, p < 0.001), and patients with CIDP (median 33 ng/mL, p < 0.001), CD (median 32 ng/mL, p = 0.001), or other plasma-cell dyscrasias (MM and AL) (median 49 ng/mL, p < 0.001) ( Figure) .
Using a receiver operating characteristic (ROC) analysis, the best P1NP cut-off for POEMS diagnosis was 70 ng/mL, with a specificity of 91.5% and a sensitivity of 80%. The area under the curve (AUC) was 0.87 (95% confidence interval [CI], 0.78-0.95, p < 0.001). The diagnostic performance of serum VEGF, a well-established biomarker for POEMS syndrome [8] , was also analyzed in these patients. The AUC was 0.89 (95% CI, 0.80-0.95, p < 0.001), and the best cut-off was 1920 pg/mL (specificity 97.6%, sensitivity 73.3%). No statistical difference was observed between these two markers for their diagnostic performance (z statistic = 0.40, p = 0.687). Moreover, fulfillment of either serum total P1NP > 70 ng/mL or serum VEGF > 1920 pg/mL could dramatically improve the diagnostic sensitivity to 91.1%, while mildly decrease the specificity to 90.2%.
As serum total P1NP is a marker of bone formation, we compared its level in POEMS syndrome patients with (n = 17) and without bone changes (n = 28). Patients with bone changes were further subdivided into those with sclerotic changes only (n = 11) and those with mixed sclerotic and lytic components (n = 6). No patient only had lytic changes. There was no statistical difference between patients with and without bone changes (median 143 vs 136 ng/mL, p = 0.519) (Supplementary figure).
We also measured the serial changes of serum VEGF and total P1NP in six patients with relapsed disease courses (Table) . For the initial therapy, five of them received a regimen of melphalan and dexamethasone and one underwent autologous stem-cell transplantation. Serum levels of total P1NP were significantly reduced after treatment and reached the normal baseline level in all but one patient. The reduction in serum markers was associated with improvements in clinical symptoms. After a certain period of remission (median, 37 months; range, 29-48 months), these patients developed new symptoms, as well as elevated serum VEGF and total P1NP levels. All of them received further therapy (lenalidomide and dexamethasone) and four patients achieved a second clinical remission during their follow-up, when they also showed reduced serum VEGF and total P1NP levels. The remaining two patients are still under treatment.
Our data indicate that serum total P1NP was markedly elevated in patients with POEMS syndrome, and had excellent diagnostic performance, which was not inferior to VEGF. Moreover, when these two biomarkers were used in parallel, the diagnosis of POEMS syndrome became more practical. These observations support the use of serum total P1NP, along with serum VEGF, as a diagnostic criterion for POEMS. With the availability of these biomarkers, the recognition of patients in infancy becomes possible, and may markedly shorten the diagnostic delay and benefit patients.
Interestingly, the serum total P1NP levels did not differ in patients with and without sclerotic changes. Regardless of the incomplete recognition of lesions by inexperienced radiologists in developing countries, we wonder whether there are much smaller or more extensive changes in these imaging-negative patients. These changes may be below the detection sensitivity of conventional imaging techniques. Therefore, bone involvement may actually be more common than previously thought and could be a defining feature of POEMS syndrome.
Another important application of serum total P1NP might be its role in disease monitoring of POEMS syndrome. Currently, VEGF is always measured before and after treatment. In the point of osteosclerosis, there is no well applicable criterion to evaluate the treatment response. Good correlations were observed for serum total P1NP levels with both clinical symptoms and serum VEGF levels in patients who experienced relapse. Theoretically, it may also have potential values for patients receiving radiation therapies against their bone lesions, as serum P1NP is a marker of bone formation. In patients with ameliorated clinical symptoms and reduced serum total P1NP levels, stable remission can be expected. However, for those with sustained high levels of serum total P1NP, salvage therapy may need to be considered carefully. Certainly, its clinical values require further examinations.
In summary, we have demonstrated, for the first time, the performance of serum total P1NP, a marker of bone formation, in the diagnosis and follow-up of POEMS syndrome.
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Methods

Patients
Forty-five consecutive patients with newly diagnosed POEMS syndrome were admitted to Peking Union Medical College Hospital from January 2009 to December 2011. These patients were treatment-naive and included in this study. Serum samples were collected and stored within 30 days of their presentation at our hospital. Another six relapsed patients, derived from the cohort with regular follow-up at our hospital, whose serial serum samples were available were also included [1] . All these patients met the diagnostic criteria proposed by Dispenzieri: (1) presence of both polyneuropathy and monoclonal gammopathy; (2) presence of one of the following three major criteria:
Castleman's disease, osteosclerosis, or elevated VEGF; and (3) one of the six minor criteria: organomegaly, extravascular volume overload, endocrinopathy, skin changes, papilledema, and either thrombocytosis or polycythemia [2] .
The detailed clinical features of the POEMS syndrome patients were recorded at the time of diagnosis. The Overall Neuropathy Limitation Scale (ONLS) score was used to assess neurological disability, as described previously [3] . Bone involvement was evaluated in all the patients with the same imaging modality, i.e. plain X-rays for skull, vertebrae, costae, pelvis, femur, and humerus. Some of the patients had bone windows of CT body imaging during their medical consultations. Laboratory data associated with POEMS syndrome were collected, including bone-marrow aspiration, serum immunoglobulin levels, and serum and urine immunofixation. Serum VEGF was measured with a human enzyme-linked immunosorbent assay (ELISA) quantikine kit (R&D systems) and the normal serum VEGF level was less than 600 pg/mL, as described elsewhere [3, 4] .
We matched newly diagnosed cases with normal or diseased controls according to age and sex. Twenty-eight normal controls were included. As the diseased controls, patients with chronic inflammatory demyelinating polyneuropathy (CIDP) (n = 18), Castleman's disease (CD) (n = 11), and other plasma-cell dyscrasias, including multiple myeloma (MM) (n = 15) or primary light-chain amyloidosis (AL) (n = 10), were recruited at the time of diagnosis, in an untreated state. As a result, 28 matched normal subjects and 54 untreated patients with disease manifestations similar to those of POEMS syndrome were included in this study.
All patients gave their informed consent and the study was approved by the Institutional Review Board of Peking Union Medical College Hospital.
Serum total P1NP measurement
Serum concentrations of total P1NP were measured, which correlate well with intact P1NP levels under most conditions [5] , using a total P1NP electrochemiluminescence kit (Elecsys, Roche Diagnostics), according to the manufacturer's instructions. The upper and lower limits of serum total P1NP (6-67 ng/mL) was defined as mean ± 3 SD of normal control values, as described for other serum factors [4] .
Statistical analyses
All analyses were performed with SPSS 17 (SPSS, Inc., Chicago, IL, USA). Sensitivity, specificity, and the area under the receiver operating characteristic (ROC) curve (AUC)
at the diagnostic cut-off points were calculated. The difference between ROC curves was analyzed with z statistic. Fisher's exact test and the Kruskal-Wallis method were used to evaluate the differences between nominal and continuous variables, respectively. For all analyses, a two-tailed p value of less than 0.05 was considered statistically significant.
